Design of a New Whole Merozoite Vaccine for Malaria
DOI:
https://doi.org/10.62051/gad8b886Keywords:
Malaria; Vaccine; Application; Security assessment; Efficiency analysis.Abstract
Malaria is one of the most fatal diseases in the sub-Saharan area, causing more than 200 million people infected and more than 600000 people dead every year. The whole society are working together to develop vaccine to prevent people from being infected. This research will focus on a new whole merozoites vaccine which contains CRISPR-Cas9 based CyRPA protein deficient merozoites. The vaccine is designed to prevent the merozoites from entering the red blood cells so it can stay in the blood, be exposed the immune system and stimulate immune response. This new vaccine can provide a durable and effective prophylactic effect if successful. The vaccine is expected to have no serious and fatal side effects and will undergo animal tests and voluntary tests to test its effectiveness. Further research will focus on resolve the remaining challenges of the vaccine, including red blood cell deformation and the possibility of merozoites still entering the blood cells.
Downloads
References
[1] D. Goswami, N. K. Minkah, S. H. I. Kappe, Malaria parasite liver stages, Journal of Hepatology 76 (3) (2022) 735-737.
[2] J. C. Volz, A. Yap, X. Sisquella, et al. Essential role of the PfRh5/PfRipr/CyRPA complex during Plasmodium falciparum invasion of erythrocytes, Cell host & microbe 20 (1) (2016) 60-71.
[3] M. L. Dubey, S. K. Rai, N. K. Ganguly, et al. Generation of reactive oxygen species by blood monocytes in human Plasmodium falciparum and P. vivax infections, Apmis 99 (1‐6) (1991) 210-212.
[4] D. Kwiatkowski, Febrile temperatures can synchronize the growth of Plasmodium falciparum in vitro, The Journal of experimental medicine 169 (1) (1989) 357-361.
[5] P. E. Duffy, J. Patrick Gorres, Malaria vaccines since 2000: progress, priorities, products, npj Vaccines 5 (1) (2020) 48.
[6] RTS, S Clinical Trials Partnership (2014), Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS medicine 11 (7) (2014) e1001685.
[7] T. L. Richie, P. F. Billingsley, B. K. L. Sim, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines, Vaccine 33 (52) (2015) 7452-7461.
[8] J. C. Volz, A. Yap, X. Sisquella, et al. Essential role of the PfRh5/PfRipr/CyRPA complex during Plasmodium falciparum invasion of erythrocytes, Cell host & microbe 20 (1) (2016) 60-71.
[9] J. G. Beeson, D. R. Drew, M. J. Boyle, et al. Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria, FEMS microbiology reviews 40 (3) (2016) 343-372.
[10] P. M. Dijkman, T. Marzluf, Y. Zhang, et al. Structure of the merozoite surface protein 1 from Plasmodium falciparum, Science Advances 7 (23) (2021) eabg0465.
[11] K. S. Reddy, E. Amlabu, A. K. Pandey, et al. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion, Proceedings of the National Academy of Sciences 112 (4) (2015) 1179-1184.
[12] H. C. Meissner, Understanding vaccine safety and the roles of the FDA and the CDC, New England Journal of Medicine 386 (17) (2022) 1638-1645.
[13] P. L. Stern, Key steps in vaccine development, Annals of Allergy, Asthma & Immunology 125 (1) (2020) 17-27.
[14] K. Hayton, D. Gaur, A. Liu, et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion, Cell host & microbe 4 (1) (2008) 40-51.
[15] J. C. Volz, A. Yap, X. Sisquella, et al. Essential role of the PfRh5/PfRipr/CyRPA complex during Plasmodium falciparum invasion of erythrocytes, Cell host & microbe 20 (1) (2016) 60-71.
[16] N. Mohandas, P G. Gallagher, Red cell membrane: past, present, and future, Blood, The Journal of the American Society of Hematology 112 (10) (2008) 3939-3948.
[17] Y. Voß, S. Klaus, J. Guizetti, et al. Plasmodium schizogony, a chronology of the parasite’s cell cycle in the blood stage, PLoS Pathogens 19 (3) (2023) e1011157.
[18] S. Basu, P. K. Sahi, Malaria: an update, The Indian Journal of Pediatrics 84 (2017) 521-528.
[19] H. Nagaoka, B. N. Kanoi, E. H. Ntege, et al. Antibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7A, Scientific Reports 10 (1) (2020) 6573.
[20] P. E. Duffy, Current approaches to malaria vaccines, Current opinion in microbiology 70 (2022) 102227.
[21] J. G. Beeson, L. Kurtovic, C. Dobaño, et al. Challenges and strategies for developing efficacious and long-lasting malaria vaccines, Science translational medicine 11 (474) (2019) eaau1458.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
